Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AM1488 是一种有效的、具有口服活性的甘氨酸受体 (GlyR) 增效剂 (hGlyRα3EC50=0.45 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 14,900 | 6-8周 | ||
50 mg | ¥ 19,420 | 6-8周 | ||
100 mg | ¥ 24,625 | 6-8周 |
产品描述 | AM1488 is a potent, orally active glycine receptor ( GlyR ) potentiator (hGlyRα3 EC 50 =0.45 μM) [1] [2]. |
体外活性 | AM-1488 also potentiates native GlyRs in mouse spinal-cord neurons, which express mostly GlyRα1(β) and GlyRα3(β) [1]. Cell Viability Assay [1] Cell Line: Mouse spinal-cord neuron Concentration: 0.5 μM Incubation Time: 10 min Result: Increased the peak current evoked by a puff of 20 μM glycine in five out of five cells, from an average of 50.8 pA to an average of 222.2 pA. |
体内活性 | AM-1488 (oral gavage; 20 mg/kg; once) treatment significantly reverse mechanical allodynia induced by nerve injury in a mouse model of neuropathic pain, without being confounded by sedation or motor side effects [1]. Animal Model: Mouse model of spared nerve injury (SNI) [1] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; once Result: Produced a significant 94% reversal of tactile allodynia, and the unbound brain concentration was 2.8- and 1.6-fold higher than the mouse GlyRα1 and GlyRα3 EC 50 values, respectively. Animal Model: Naive mice [1] Dosage: 20 mg/kg Administration: Oral gavage; 20 mg/kg; once Result: Showed not significantly different from mice treated with vehicle. |
分子量 | 383.42 |
分子式 | C19H17N3O4S |
CAS No. | 2079895-60-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AM-1488 2079895-60-4 Inhibitor inhibitor inhibit